Hopewell Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HOPEWELL PHARMA
HOPEWELL PHARMA has one approved drug.
Summary for Hopewell Pharma
| US Patents: | 0 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
| PTAB Cases with Hopewell Pharma as petitioner: | See PTAB cases with Hopewell Pharma as petitioner |
Drugs and US Patents for Hopewell Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hopewell Pharma | CLADRIBINE | cladribine | TABLET;ORAL | 215547-001 | Mar 27, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
